Insmed Inc - INSM - reported that the FDA has lifted the clinical hold previously placed on ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria lung disease. Schlumberger Ltd - SLB - posted full-year 2011 revenue of $39.54 billion versus $27.45 billion in 2010. and lastly; Biodel Inc - BIOD - reported that the European Medicines Agency's Committee for Orphan Medicinal Products has recommended that Biodel's Stabilized Glucagon for the treatment of congenital hyperinsulinism be granted Orphan Medicinal Product Designation. ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

• Added by: karmastock
• Date added: 20/01/12
• Video Duration: 01:13
• Category: News
• Number of views:425
• Tags: Insmed, Schlumberger, Biodel, INSM, SLB, BIOD, Nasdaq:INSM, NYSE:SLB, Nasdaq:BIOD (SLB, BIOD, INSM) CRWENewswire Stocks In Action



Post a Comment

To add a comment, please fill out the box below and click on the submit button. Comment:

There are currently no comments for this video